Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 5 (5): Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
imported>GxPlexBot Import from GxPlex Excel |
||
| Line 5: | Line 5: | ||
(5) | (5) | ||
|RefLanguage=EN | |RefLanguage=EN | ||
| | |RefTags=TAG-00269-Wit-der ++ TAG-00039-Tem-ung ++ TAG-00038-Ear-tig ++ TAG-00057-Com-deR ++ TAG-00041-Ame-run | ||
| | |RefModule=6 | ||
| | |RefUnit=6.1.2 | ||
}} | }} | ||
| Line 15: | Line 15: | ||
|- | |- | ||
! colspan="2" class="gplx-infobox-header" | Reference Details | ! colspan="2" class="gplx-infobox-header" | Reference Details | ||
|- | |||
! Module | |||
| Module 6 — Unit 6.1.2 | |||
|- | |- | ||
! Scope | ! Scope | ||
| Line 32: | Line 35: | ||
| | | | ||
|- | |- | ||
! Tags | ! Tags | ||
| | | [[Glossary:TAG-00269-Wit-der|Authorisation revocation]], [[Glossary:TAG-00039-Tem-ung|Temporary halt]], [[Glossary:TAG-00038-Ear-tig|Early termination]], [[Glossary:TAG-00057-Com-deR|Competent authority]], [[Glossary:TAG-00041-Ame-run|Amendment]] | ||
|- | |||
| | |||
|- | |||
| | |||
|- | |- | ||
! Comment | ! Comment | ||
Revision as of 17:29, 15 July 2026
| Document information | |
|---|---|
| Reference | GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 |
| Validity area | GBR |
| Scope(s) | HM |
| Document name | The Medicines for Human Use (Clinical Trials) Regulations 2004 |
| Version / Revision | 01-May-2004 |
| Status | Current |
| Document type | Legal act |
| Language(s) | EN |
| Description | The Medicines for Human Use (Clinical Trials) Regulations 2004 |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 6 — Unit 6.1.2 |
| Scope | HM |
| Document part | Schedule 5
(5) |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Authorisation revocation, Temporary halt, Early termination, Competent authority, Amendment |
| Comment | Procedural provisions on refusal or amendment of authorisation |
Content
PROCEDURAL PROVISIONS RELATING TO THE REFUSAL OR AMENDMENT OF, OR IMPOSITION OF CONDITIONS RELATING TO, CLINICAL TRIAL AUTHORISATION AND THE SUSPENSION OR TERMINATION OF CLINICAL TRIALS 1.— […] (5) In the case of a notice to suspend or terminate a trial, the licensing authority shall, after considering the report of the appropriate committee or the Commission, confirm or revoke the notice. [...] 3.— [...] (4) The decisions to which this paragraph applies are decisions of the licensing authority— (a)to confirm— (i)that they have grounds for not accepting a request for authorisation or an amendment to the clinical trial authorisation, (ii)their decision to impose a condition, or (iii)the notice to suspend or terminate the trial,against the advice of the Medicines Commission under paragraph 1(2);
